Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Sophie Piperno‐Neumann, Matteo S. Carlino, Valentina Boni, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 6, pp. 1040-1051
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Artificial intelligence in drug development: reshaping the therapeutic landscape
Sarfaraz K. Niazi, Zamara Mariam
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access | Times Cited: 2
GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma
Paula Silva, Daniel Fernández‐Díaz, Manuel F. Bande, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3066-3066
Open Access | Times Cited: 56
Uveal melanoma: In the era of new treatments
Mylène Wespiser, Ève-Marie Neidhardt, Sylvie Négrier
Cancer Treatment Reviews (2023) Vol. 119, pp. 102599-102599
Closed Access | Times Cited: 23
The future of pharmaceuticals: Artificial intelligence in drug discovery and development
Chen Fu, Qi Chen
Journal of Pharmaceutical Analysis (2025), pp. 101248-101248
Open Access | Times Cited: 1
Darovasertib, a novel treatment for metastatic uveal melanoma
Lei Cao, Shuzhen Chen, Rainie Sun, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
Uveal melanoma: progress in molecular biology and therapeutics
Yongyun Li, Jiahao Shi, Jie Yang, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 48
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
Michael Visser, Julien P. N. Papillon, Michael J. Luzzio, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1447-1459
Closed Access | Times Cited: 5
Targeted therapy in ophthalmic oncology: The current status
Mrittika Sen, Hakan Demirci, Santosh G Honavar
Asia-Pacific Journal of Ophthalmology (2024) Vol. 13, Iss. 2, pp. 100062-100062
Open Access | Times Cited: 5
Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
John Park, Ashleigh Stewart, Mal Irvine, et al.
Cancer Gene Therapy (2022) Vol. 29, Iss. 10, pp. 1384-1393
Open Access | Times Cited: 19
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma
Nadia Arang, Simone Lubrano, Michele Ceribelli, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101244-101244
Open Access | Times Cited: 12
Prognostic and predictive biomarkers in melanoma
Nigel Maher, Ismael A. Vergara, Georgina V. Long, et al.
Pathology (2023) Vol. 56, Iss. 2, pp. 259-273
Closed Access | Times Cited: 12
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
John Park, Sabine Abou Hamad, Ashleigh Stewart, et al.
Oncogenesis (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Updates in the Management of Uveal Melanoma
Mali Barbi, Richard D. Carvajal, Craig Devoe
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 92-101
Closed Access | Times Cited: 4
Harnessing p53 for targeted cancer therapy: new advances and future directions
Zdeněk Andrysík, Joaquı́n M. Espinosa
Transcription (2025), pp. 1-44
Open Access
How we treat patients with metastatic uveal melanoma
Erick Figueiredo Saldanha, Maria Flávia Marques Ribeiro, Ian Hirsch, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104496-104496
Closed Access
Current Therapies and Potential Strategies for Uveal Melanoma
Sarah Scoles, Sanjay Ganesh, Kaori Yamada
Drugs and Drug Candidates (2025) Vol. 4, Iss. 2, pp. 14-14
Open Access
Utility of Protein Kinase C Beta II Immunohistochemistry in Differential Diagnosis of Ewing Sarcoma
Jerzy Lasota, Martyna Krupińska, Maciej Kaczorowski, et al.
The American Journal of Surgical Pathology (2025)
Closed Access
Uveal Melanoma: Adjuvant and Neoadjuvant Therapy
Shaheer Khan, Jessica Yang, Arun D. Singh, et al.
Clinical ophthalmic oncology (2025), pp. 317-326
Closed Access
Uveal Melanoma: Metastases
Lucy Boyce Kennedy, Arun D. Singh
Clinical ophthalmic oncology (2025), pp. 327-344
Closed Access
Genetic Landscape and Emerging Therapies in Uveal Melanoma
Rino S. Seedor, Marlana Orloff, Takami Sato
Cancers (2021) Vol. 13, Iss. 21, pp. 5503-5503
Open Access | Times Cited: 24
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Elias A. T. Koch, Markus V. Heppt, Carola Berking
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 5, pp. 691-700
Open Access | Times Cited: 3
Genetics and Current Research Models of Mendelian Tumor Predisposition Syndromes with Ocular Involvement
Lola P. Lozano, Roy A. Jensen, Madeleine K. Jennisch, et al.
Progress in Retinal and Eye Research (2025), pp. 101359-101359
Open Access
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
Alexander N. Shoushtari, Shaheer Khan, Kimberly M. Komatsubara, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5504-5504
Open Access | Times Cited: 23
FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
Malcy Tarin, Fariba Némati, Didier Decaudin, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2280-2280
Open Access | Times Cited: 9
Evolving Management of Stage IV Melanoma
Benjamin Switzer, Sophie Piperno‐Neumann, J. F. Lyon, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top